Acadia Pharmaceuticals | ACAD - Net Income

Stock Price
22.25
Daily Change
0.05 0.23%
Monthly
-1.11%
Yearly
38.03%
Q2 Forecast
21.53

Acadia Pharmaceuticals reported $273.57M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
Acadia Pharmaceuticals USD 273.57M 201.79M Dec/2025
ALKERMES USD 49.34M 33.42M Dec/2025
Alnylam Pharmaceuticals USD 186.42M 64.66M Dec/2025
Biogen USD 466.5M 168.3M Sep/2025
BioMarin Pharmaceutical USD -46.57M 15.83M Dec/2025
Bristol-Myers Squibb USD 1.09B 1.11B Dec/2025
Cara Therapeutics USD -5.53M 621K Sep/2025
Corcept Therapeutics USD 24.29M 4.62M Dec/2025
Cytokinetics USD -183.03M 123.15M Dec/2025
Eisai JPY 17.18B 7.02B Dec/2025
Eli Lilly USD 6.64B 1.05B Dec/2025
Incyte USD 299.28M 124.89M Dec/2025
J&J USD 5.12B 36M Dec/2025
Moderna USD -200M 625M Sep/2025
Neurocrine Biosciences USD 209.5M 102M Sep/2025
Pfizer USD -1.65B 5.19B Dec/2025
Prothena USD -21.59M 14.95M Dec/2025
PTC Therapeutics USD -134.96M 150.86M Dec/2025
Sarepta Therapeutics USD -412.23M 232.28M Dec/2025
Ultragenyx Pharmaceutical USD -129M 51.41M Dec/2025
Vanda Pharmaceuticals USD -18.9M 13.58M Dec/2024
Vertex Pharmaceuticals USD 1.19B 108.2M Dec/2025